Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors

Table 2

Multivariable logistic regression model describing the association of clinicopathological and treatment characteristics with clinical response (prob > chi2 = 0.0048; pseudo  = 0.3740).

Partial response	OR (odds ratio)	Std. err.	> |z|	95% CI
CTCAE grading 1	Ref
CTCAE grading 2	0.011	0.017	0.006	0.0004–0.2664
CTCAE grading 3	0.003	0.006	0.006	0.00004–0.174
Female	Ref
Male	0.09	0.126	0.091	0.005–1.4707
Age	0.94	0.049	0.249	0.8502–1.0429
EGFRi
Cetuximab	Ref
Afatinib	1.73	2.305	0.682	0.1263–23.623
Osimertinib	1.38	3.902	0.910	0.0053–355.86
Gefitinib	2.21	4.445	0.694	0.0428–114.04
Panitumumab	4.25	5.667	0.278	0.4964–820.65
MEST grading 1 (1a/1b)	Ref
MEST grading 2 (2a/2b)	0.10	0.136	0.092	0.0067–1.4631
MEST grading 3 (3a/3b)	0.01	0.017	0.009	0.00031–0.3114
Female	Ref
Male	0.29	0.339	0.289	0.0314–2.7972
Age	0.96	0.047	0.362	0.8683–1.0528
EGFRi
Cetuximab	Ref
Afatinib	1.68	2.262	0.701	0.1196–23.5546
Osimertinib	0.57	1.123	0.776	0.0121–26.9324
Gefitinib	1.61	2.687	0.775	0.0611–42.4065
Panitumumab	1.40	6.656	0.151	0.15100–217892.7

Bold values are statistically significant.